# Claim Denial A **claim denial** is an insurer's refusal to pay for a service — either prospectively (via [[Prior Authorization]]) or after the fact. Denials are a normal part of [[Managed Care]] adjudication, but their volume, opacity, and inconsistency have made them the most politically combustible practice in U.S. health insurance. ## Types of Denials Denials fall into two broad categories. A **prospective denial** occurs when an insurer refuses to authorize a service before it is delivered, routing through [[Prior Authorization]]. A **retrospective denial** occurs after care has already been provided, leaving either the patient or the provider holding an unexpected bill. Within those categories, insurers cite clinical grounds (the service is deemed "not medically necessary"), administrative grounds (a form was filed late or coded incorrectly), or network grounds (the provider is out of network). The practical effect is the same: care is blocked or its cost is shifted to the patient, and the insurer retains the premium revenue. ## Denial Rates and the Numbers Denial rates vary by insurer and market segment, but the scale is enormous. In [[Medicare Advantage]] plans, average prior-authorization denial rates run around 12 percent; in [[Medicaid]] managed-care organizations roughly 14 percent; and in [[Affordable Care Act]] marketplace plans as high as 18 percent. [[UnitedHealth Group]] consistently leads: its [[Medicare Advantage]] denial rate has been measured at 17 percent, and its ACA marketplace denial rate reached 33 percent in 2023 before falling to about 20 percent the following year. [[Cigna]], [[Humana]], and [[CVS Health]] post comparable numbers in specific service categories — [[CVS Health]] denied 80 percent of post-acute-care requests in one study. The most politically damaging statistic is the **overturn rate on appeal**. When [[Medicare Advantage]] enrollees appeal a denial, insurers collectively reverse more than one-third of their own decisions — implying that a large share of initial refusals were not medically justified. In [[Medicaid]] managed care the overturn rate is 47 percent; in the ACA marketplace, 43 percent. Yet fewer than one percent of denied patients ever file an appeal, meaning the denial itself is functionally final for the vast majority. ## Automated and Algorithmic Denials The rise of [[Artificial Intelligence]] in claims adjudication intensified the controversy. A 2022 Senate investigation found that [[UnitedHealth Group]], [[Humana]], and [[CVS Health]] used predictive-algorithm tools to deny [[Medicare Advantage]] claims at scale. [[UnitedHealth Group]]'s internal tool, nH Predict, was deployed to review post-acute-care requests; the company's denial rate for skilled-nursing-facility admissions rose from 1.4 percent in 2019 to 12.6 percent in 2022 — a ninefold increase that tracked directly with the algorithm's rollout. A subsequent class-action lawsuit alleged the company knew the tool had a 90-percent error rate, meaning nine of ten denials were reversed when challenged. The episode illustrated how denial can be **optimized at scale** when the insurer bets — correctly — that most patients will never appeal. ## The Appeals Gap The asymmetry between denial volume and appeal volume is the mechanism that makes claim denial profitable. Insurers issue millions of denials annually; patients appeal a tiny fraction; and when they do, they win at rates that suggest the denial should not have been issued. The structural barriers to appeal — complexity of paperwork, short filing windows, lack of patient awareness, illness itself — function as a [[Rent-Seeking]] friction that converts administrative hassle into margin. [[CMS]] and state regulators have tried to narrow this gap through transparency requirements and expedited-review rules, but the basic incentive — every dollar not paid out is a dollar retained — persists under the [[Managed Care]] model. ## Political Salience Claim denial is the proximate grievance behind the **insurer-populism wave**: the December 2024 [[UnitedHealthcare CEO Shooting]] and the killing of [[Luigi Mangione]]'s target detonated a torrent of public anger that crossed ordinary partisan lines. The viral response revealed how deeply the denial experience had penetrated everyday life — patients, nurses, and physicians shared stories that framed denial not as a bureaucratic nuisance but as a life-threatening act. The critique connects denial to the [[Managed Care]] business model, to the broader [[Healthcare Industry Ecosystem]], and to the political economy of [[Lobbying]] and [[Regulatory Capture]] that shields the industry from reform. Legislators including [[Bernie Sanders]], [[Elizabeth Warren]], and [[Katie Porter]] seized the moment to push denial-transparency and appeals-reform bills, though the [[Heritage Foundation]], [[American Enterprise Institute]], and [[Cato Institute]] countered with arguments about cost containment and [[Deregulation]]. ## See Also - [[Prior Authorization]], [[Managed Care]], [[Medicare Advantage]] - [[UnitedHealthcare CEO Shooting]], [[Luigi Mangione]] - [[Healthcare Industry Ecosystem]] - [[Affordable Care Act]], [[CMS]] - [[Regulatory Capture]], [[Rent-Seeking]], [[Corporate Power]]